Epithelial ovarian cancer  : A clinical epidemiological approach on diagnosis and treatment by Paulsen, Torbjørn
Epithelial ovarian cancer 
A clinical epidemiological approach on 
diagnosis and treatment 
Torbjørn Paulsen 
Oslo February 2007 
© Torbjørn Paulsen, 2007 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No.549
ISBN 978-82-8072-439-7
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS, Oslo, 2007.   
Produced in co-operation with Unipub AS.  
The thesis is produced by Unipub AS merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
Unipub AS is owned by  
The University Foundation for Student Life (SiO)
“It is the business if the physicians to know, in the first place, things similar 
and things dissimilar; those connected with things most important, most 
easily known, and in anywise known; which are to be seen, touched, and 
heard; which are to be perceived in the sight, and the touch, and the 
hearing, and the nose, and the tongue, and the understanding: which are to 
be known by all means we know other things.” 
Hippocrates1
“Read not to contradict, nor to believe, but to weigh and consider”
Bacon2
3
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ABBREVIATIONS
BRAF v–raf murine sarcoma viral oncogene homolog B1. Chromosome: 
7q34
CEA  Carcinoembryonic antigen 
CT   Computer tomography 
EOC  Eithelial ovarian cancer 
FIGO  International Federation of Gynaecology and Obstetrics 
GYN  Gynaecological 
HLA–G HLA–G histocompatibility antigen, class I,G. Chromosome: 6q213 
HR   Hazard ratio 
HS   Haematoxylin staining 
ICD–10  International Classification of Disease – Version 10 
KRAS v–Ki–ras2 Kristen rat sarcoma viral oncogne. Chromosome: 
12p12.1
MMP Matrix metallinoproteases 
MRI  Magnetic resonance imaging 
NTH   Non–teaching hospitals 
OR   Odds ratio 
OVANOR Population–based clinical register of ovarian cancer in Norway, 
established in 2002 
TH   Teaching hospitals 
TP53  tumour protein p53 gene 
RMI  Risk of malignancy index 
S–BOT  Serous borderline ovarian tumours (= SBT) 
SCI  Surgery chemotherapy interval 
TIMP  Tissue inhibitors of metalloproteases 
VEGF  Vessel endothelial growth factor 
VEGFR   Vessel endothelial growth factor reseptor 
WHO  World Health Organization 
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AIMS
The main aim was to reveal shortcomings in diagnosis and treatment for epithelial 
ovarian cancer (EOC) patients in order to improve diagnostic procedures and therapy 
together with increased biological knowledge. A systematic registration of all ovarian 
cancer patients on a national level was performed with a focus on symptoms, diagnosis, 
surgery, and chemotherapy.
Paper 1 
We hypothesized that a large proportion of epithelial ovarian cancer patients were 
referred to non–gynaecological (GYN) units in Norway. The aim was to investigate how 
symptoms influenced referral of patients to different hospital units. 
Paper 2 
We hypothesized that advanced EOC patients treated at teaching hospitals (TH) 
had improved survival compared to those treated at non–teaching hospitals (NTH). The 
aim was to evaluate the impact on survival of hospital level and operating physician’s 
speciality.
Paper 3 
In animal models, short surgery chemotherapy interval (SCI) improve survival, 
therefore we hypothesized that advanced EOC patients with short SCI had improved 
survival. The aim was to demonstrate the possible survival impact of SCI for EOC patients. 
Paper 4 
In EOC, high levels of MMP and VEGF are associated with metastic spread of 
disease3;4. We considered that non–invasive implant formation in borderline ovarian 
tumors (BOT) followed the same principle as metastasis formation in EOC. The aims were 
to illuminate the biological mechanisms of non–invasive implant formation and to 
investigate the prognostic effect from the presence of non–invasive implants on disease–
free survival. 
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GENERAL INTRODUCTION
Symptoms
Two thirds of EOC patients are diagnosed primarily with advanced disease, 
probably because symptoms are vague and nonspecific in early stages. The patient may be 
asymptomatic when an abdominal mass is discovered during routine pelvic examination. 
This is often the case for patients with BOT. Abdominal pain, distended abdomen, bowel 
irregularity, and persisting fatigue are frequent symptoms in advanced EOC patients. The 
sensation of an abdominal mass is shown to be more common in women with ovarian 
cancer than other pelvic cancers5. Abdominal pain is often caused by pressure of the 
tumour against abdominal organs. Distended abdomen, ascites and subileus may also cause 
abdominal pain. Infiltrative growth in the intestines may cause bowel irregularities as 
constipation, small stool diameter, ileus or rectal bleeding. Some patients experience 
vaginal bleeding or discharge, urinary urgency, and respiratory difficulties. The latter 
symptom may be caused by distended abdomen with pressure against the diaphragm, and 
pleural efusion. Acute symptoms, as pain due to rupture or torsion, are infrequent6;7. Some 
women with EOC may falsely be diagnosed as gastritis, irritable bowel syndrome, stress or 
depression8. In paper 1, we described the symptoms of EOC and BOT patients. 
Incidence and prevalence of ovarian cancers 
The age–standardised incidence rate for EOC has not changed much during the last 
decades. The incidence of EOC was 9.3 per 100 000 women–years in 1957 and 11.6 in 
2004 in Norway (Figure 1)9. The rates in the Scandinavian countries are among the highest 
in the world. World wide there are 204 000 new cases of ovarian cancer diagnosed 
annually with an estimated 125 000 disease related deaths10. The incidence rate of BOT 
was 5.0 per 100 000 women–years in 2004 9. The prevalencea of EOC and non–EOC 
patients in Norway was 3521 in 1994 and 4104 in 2004. For BOT the prevalence were 
1287 in 1994 and 2283 in 2004. The majority of EOC patients are not cured, while most 
BOT patients are cured. In the general population the lifetime risk for developing EOC is 
1.4 %11.
There was a fall in incidence of EOC from 12.8 per 100 000 women–years in 2002 
to 10.5 in 2003, which might be explained by a variation by chance. In 2004 the incidence 
was 11.6 thus no trend was seen. 
a Patients cured and living with disease 
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The World Health Organization’s (WHO) introduction of a more precise 
pathological definition of BOT12 has probably lead to an increasing incidence of BOT 
(Figure1).
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Figure 1. Age–adjusted incidence rates for all stages 1953 to 2004 for patients with 
epithelial ovarian cancer (EOC), non–EOC and borderline ovarian tumors (BOT) in 
Norway. Data from Cancer Registry 
Mortality and survival
EOC is the female genital cancer with the highest mortality in the western world13.
The five–years relative survival for patients with EOC in Norway has improved over time, 
but is still only 42 % for all stages (1995 – 1999; personal communication: Bjørge Sæther, 
Cancer Registry). In the time period 1995 – 1999 five–years survival for patients with 
localized disease EOC is 90 %. BOT has much better survival, both in localized and 
advanced stages. Five–years survival is 99 % in stage I14, 98 % in S–BOT with non–
invasive implants and 33 % in those patients with invasive implants15.
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Figure 2. Five–years relative survival by stage for epithelial ovarian cancer (EOC), 
diagnosed in the period 1955 – 1999. Data from Cancer Registry 
Histology (Table 1) 
Epithelial ovarian cancers (EOC) 
These tumours constitute more than 90 % of all ovarian tumours16.
EOC are classified as serous (63 %), endometroid (12 %), mucinous (9 %), clear cell (7 %) 
while other types (9 %) comprise the rest of the tumours (Paper 1). 
Borderline ovarian tumours (BOT) 
BOT consist of the epithelial subgroups: serous (56 %), mucinous (42 %), 
endometroid (2 %), and others (< 1 %) (Paper 1). According to WHO’s classification17, S–
BOT consist of the typical (90 %) and the micropapillary type (5 – 10 %). Some tumours 
might be associated with peritoneal implants of either non–invasive or invasive type. S–
BOT might develop into low grade serous carcinoma via the “low–grade” pathway18;19
(Figure 3). 
Non–epithelial ovarian cancer patients were excluded from the analyses in the 
present thesis because these cancers have a different genetic origin and are treated with less 
extended surgery and other chemotherapeutic regimens than EOC patients. The survival 
pattern is also different20.
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Table 1. WHO’s histological classification of ovarian cancers17
Main type Subtype
Included
in the 
thesis
Included in 
OVANOR
registry
Epithelial
EOC (including tubal 
and peritoneal cancer)
Serous, mucinous, endometroid, 
clear cell, transitional, squamous, 
mixed epithelial tumours, 
undifferentiated
yes yes
BOT Serous, mucinous, endometroid, 
clear cell, transitional, squamous, 
mixed epithelial tumours 
yes yes
Non–epithelial
Sexcord stromal, germ cell, 
tumours of the rete ovarii, 
miscellaneous tumours, tumour 
like conditions, lymphoid and 
haematopoetic tumours, secondary 
tumours 
no yes
Epithelial ovarian cancer is defined as epithelial ovarian cancer (EOC) and
borderline ovarian tumours (BOT) 
Ovarian cancer is defined as epithelial and non–epithelial ovarian cancers
Etiology and risk factors 
Although the causes of EOC remain uncertain, hypotheses relating to incessant 
ovulation21, excessive gonadotropin secretion, retrograde (asbestos and talc) carcinogen 
transportation22;23 and estrogen/progestin imbalance have been suggested as etiological 
explanations for developing EOC. The epidemiological evidence for these hypotheses is 
not consistent. Some evidence supports estrogen, although stronger evidence implicates 
factors related to androgens and progesterone as ethiological factors24. Familial history 
make up approximately 10 % of the causes while the rest spontaneously occurring25.
Polycystic ovarian syndrome, pelvic inflammatory disease, obesity, endometriosis, and 
hormonal replacement therapy during menopause have been shown to increase the risk of 
EOC26-28. Data on obesity is conflicting. Some authors have demonstrated an increased risk 
of EOC with increasing body mass index27, while others have shown a lower risk. 
However, obese women had a higher frequency of BOT28.
Multiple births, breastfeeding and contraceptive pills appear to protect against EOC. 
Tobacco smoking may reduce the risk29. The use of nonsteroid anti–inflammatory drugs 
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have also been discussed as protectors30. Surgical ligation of the phallopian tubes and 
hysterectomy may also reduce the risk26. Epidemiological data on the association with 
physical activity and EOC is however conflicting31;32.
Prognostic variables
Many prognostic variables have been described for EOC. The most important 
variables used in the clinical setting are: residual disease, FIGO stage, ascites, grade of 
differentiation, histologic type, age, performance status (WHO)33 , CA–125 levels at 
diagnosis and post–surgery, and DNA ploidy34. These prognostic variables are examined in 
the papers making up this thesis. 
Possible prognostic variables 
Many studies have been published that characterize tumours based on over– or 
under– expression of a multitude of genes (TP53, HER2, Bcl–2, Ki–67, PDGFRa, MMP–
2, P–glycoprotein, VEGF–C, VEGFR–2, MVD, AP–2Ȗ, MAP2K4 gene, MAD1L gene, 
and serine proteinase genes35-39). Researchers have identified malignant phenotypes based 
on gene expression profiles, distinguished BRCA–1 and BRCA–2 from germline tumours, 
and classified borderline tumours based on protein expression 40;41. Some studies have been 
performed on EOC using microarrays42;43. These studies are promising with regard to 
predicting optimal surgery and chemotherapy resistance43.
Pathogenesis
Cancer is an acuired genetic disease in which a single clone of cells and its progeny 
accumulate heritable changes that results in the cellular phenotype of cancer44. The cells 
evolve progressively from normality via a series of premalignant states into invasive 
cancers45. Cancer cells have defects in regulatory circuits that govern normal cell 
proliferation and homeostasis46. Hanahan and Weinberg proposed six essential alterations 
in cell physiology that collectively dictate malignant growth: self–sufficiency in growth 
signals, insensitivity to growth–inhibitory signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, tissue invasion and 
metastasis46.
Genetic mutations that involve DNA repair such as BRCA, MSH–2, MLH–2,   
PMS 1 and PMS 2 gene mutations appear to increase the risk of EOC47.
Recently a new theory has been developed, describing a subset of serous ovarian 
cystadenomas that evolve through S–BOT to low–grade EOC19 (Figure 3). This “low–
grade” pathway involves mutations in the BRAF/KRAS signalling pathway. The pathway 
involves S–BOT as a precursor mimicking the adenocarcinoma sequence in colorectal 
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cancer in which carcinoma evolves through a continuum of histological precursor lesions. 
Only 2 % of all S–BOT progress to carcinoma via the “low–grade” pathway48. Earlier it 
has been proposed that EOC did not have a premalignant phase like many other cancers 
(breast, cervical, colorectal), but developed rapidly from inclusion cysts into an invasive 
and widespread stage49;50. This “high–grade” pathway was also included in the new theory 
by Shih and Kurman18;19 . The latter pathway involved frequent TP53 mutations and very 
seldom BRAF/KRAS mutations. No precursor has until now been identified in the “high–
grade” pathway. EOC probably develops via either of these two pathways. In paper 4 we 
disussed some aspects of the “low–grade” pathway. 
High-grade pathway
High-grade carcinoma
Figure 3. “Low–grade” pathway: frequent BRAF/KRAS mutations (61 – 68 %), low 
cellular proliferation, gradual increase in chromosomal instability, five–year survival       
| 55 %; “High–grade” pathway: frequent TP53 mutations (70 %), high cellular 
proliferation, high chromosomal instability, frequent HLA–G expression, five–years 
survival | 30 %. APST: Atypical proliferative serous tumours, SBT = S–BOT = Serous 
borderline ovarian tumours, MPSC: Micropapillary serous carcinoma 18. The figure was 
presented in a lecture by R. J. Kurman on Crete, June 2006. With permission 
Tissue invasion and metastasis
Matrix metallinoproteases (MMP) and vessel endothelial growth factors (VEGF) 
play an important role in cell physiology leading to tissue invasion and metastasis. In 1962 
Gross and Lapière first described the MMP in metamorphosis in frogs51. Growth factors 
and oncogenes induce the expression of genes expressing extracellular matrix–degrading 
proteins. These enzymes are capable of degrading basement membrane and connective 
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tissue proteins. Recently, it has become clear that these enzymes contribute to many stages 
in tumour progression, including growth, angiogenesis, and development of early stage 
tumours. In addition, their substrates are much broader than matrix components alone, and 
include growth factors, together with their receptors, chemokines, apoptotic factors, and 
adhesion molecules. The MMP are required in many biological processes such as 
embryogenic development, organ morphogenesis, angiogenesis, cartilage remodeling, bone 
growth and wound healing52;53.
One of the major structural components of the basement membrane, the type IV 
collagen, is substrate for MMP–254 and is highly degraded during tumour cell invasion. 
Like most metallinoproteases, MMP–2 is secreted as a proenzyme, which is processed 
extracellularly to generate an active gelatinase55;56. This activation process has a complex 
mechanism57 involving a membrane–bound MMP termed membrane–type 1 (MT1) MMP, 
or MMP–14. A specific MMP–2 inhibitor, the type 2 tissue inhibitor of MMP (TIMP–2)58,
probably exercises its inhibitory function near the MMP–14 binding sites. The mechanism 
of MMP–2 activation also involves TIMP–2 bound to the MMP–2 and MMP–1459. The 
matrix degrading enzymes might contribute to the development of a variety of pathological 
conditions by misregulation. In paper 4 the MMP and VEGF were used to illuminate the 
biological mechanisms in non–invasive implant (metastasis) development in S–BOT. 
Hospital level
In Norway, EOC and BOT patients are treated at three hospital levels; local 
hospitals (n = 40), central hospitals (n = 12), and regional hospitals (one hospital in each of 
the four Health Regions). Only the regional hospitals include gynaecological oncology 
units and medical schools. The regional hospitals were defined as teaching hospitals (TH) 
and the others as non–teaching hospitals (NTH). Paper 2 address, differences in patient 
outcome between these two hospital levels. 
Staging
The majority of EOC patients have widespread tumour dissemination in the 
abdominal cavity at time of diagnosis. During the period 1992 – 1997 in the United States, 
58 % of women with ovarian cancer had distant spread. Thirteen percent had regional 
spread, 20 % localized, and 9 % were unstaged (based on 53711 cases)60. In 
gynaecological departments the FIGO staging system is used (Appendix 12.1)61. The 
system is based on a detailed description of tumour spread inside and outside the 
abdominal cavity at primary surgery. The maximum tumour diameter is registrated in 
centimetres. Tumour spread outside the abdominal cavity must be verified by biopsy or 
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cytology. Stage migration is defined as microscopic spread (verified by biopsy) outside the 
ovaries (omentum, peritoneum, lymph nodes, or other organs) in suspected lower stage 
disease. The performace of a more exact staging procedure will lead to stage migration. In 
paper 1 we showed the distribution of FIGO stages in EOC and BOT patients (Figure 4). 
Figure 4. Primary epithelial ovarian cancers in Norway according to FIGO stage 
(Appendix 12.1)61, diagnosed 2002. 
A. Epithelial ovarian cancers (EOC) (n = 486): 1A (8 %), 1B (1 %), 1C (10 %), 2A (2 %), 
2B (3 %), 2C (5 %), 3A (3 %), 3B (4 %), 3C (43 %), 4 (16 %), unstaged (6 %). 
B. Borderline ovarian tumours (BOT) (n =137): 1A (52 %), 1B (4 %), 1C (31 %), 2A (4 
%), 2B (4 %), 2C (4 %), 3A (1 %), 3B (4 %), 3C (0 %), unstaged (1 %). Data from 
OVANOR registry 
Treatment
Surgery
EOC patients in stages I and II are treated with peritoneal cytology, random 
peritoneal biopsies, total abdominal hysterectomy, bilateral salpingoopherectomy, 
omentectomy, pelvic/paraaortic lymphadenectomy62, and appendectomy in selected cases 
(mucinous tumours). Lymphadenectomy is performed in order to rule out tumour spread 
outside the ovaries63. BOT patients in stages I to III are treated with peritoneal cytology, 
random peritoneal biopsies, total abdominal hysterectomy, bilateral salpingoopherectomy, 
omentectomy, pelvic/paraaortic lymp node sampling, and appendectomy in selected cases 
(mucinous tumours). 
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Young women with EOC and BOT with non–clear cell tumours in stage IA,    
grade 1, diploid, and normal CA–125 level (< 35 kU/liter) preoperativly might be managed 
conservatively with preservation of their reproductive potential64. Only retrospective 
studies support this treatment modality. The operating physcican must discuss the option of 
preserving fertility with the patient before surgery. 
The recomended operation on women with advanced EOC includes total abdominal 
hysterectomy, bilateral salpingoophorectomy, complete omentectomy, resection of any 
tumour lesions on the peritoneal surface in the abdominal cavity (liver, spleen, diaphragm), 
pelvic, and paraaortic lymph node sampling or lymphadenectomy16. In cases of tumour 
spread to the bowel where optimal cytoreduction can be accomplished removal of the 
bowel is recommended. The principle of maximum cytoreductive surgery for advanced 
EOC was first described in the thirties by Meigs65 and later supported by a study of Aure et 
al.66. Among 102 patients Griffiths et al.67 demonstrated that a reduction of residual disease 
to less than 1.6 cm irrespective of the number of remaining tumours resulted in improved 
survival. Other studies have confirmed these findings68-72. Bristow et al. fitted a regression 
model to 81 patient cohorts a total of 8865 patients, showing that a 10 % increase in 
maximal cytoreduction was associated with 5.5 % increase in median survival time73. In 
recent years, surgical techniques have been developed in order to achieve maximal tumour 
reduction74-78. The benefit of performing extensive surgery in the upper abdomen for 
women with widespread disease is still debated 79;80.
Many authors have questioned whether the resectability of a tumour is a reflection 
of biology or surgical skill79;81-83. These authors claim that optimal surgery is dependent on 
tumour biology. Crawford et al. found that patients in stage IC – IIC EOC that were 
optimally debulked had a survival benefit compared to patients in stage III – IV EOC also 
being optimal debulked 79. This study had limited information on substages. The authors 
concluded that a selection of patients to aggressive debulking should be done in patients 
with preoperatively less extensive disease. This is in contrast to the findings of Eisenkop et 
al., which demonstrated that cytoreduction to no residual disease has a more significant 
influence on survival regardless of disease extention before surgery84. Only patients in 
stage IIIC were included in this study. However, there was no information on residual 
tumour volume, which is an important prognostic factor. These differences in methodology 
might explain the different outcome among these studies. 
In a recently published paper from the United States, the hospital and the surgeons’ 
operating volume were not associated with improved survival85. A lack of accurancy in 
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registration might be one explanation why operating volume was not associated with better 
outcome. Other authors have shown that surgery by a consultant gynaecological 
oncologists improved the outcome for EOC patients10;72;86-91.
Several authors have shown that treatment at a higher hospital level was associated 
with better prognosis92-95. In a retrospective Finish study the patients had more extensively 
surgery at TH and better outcome compared to NTH92. In paper 2 we used a prospective 
design to examine the hospital level and surgeon specialty effect on patients’ survival.
Chemotherapy
The introduction of postoperative chemotherapy in advanced EOC treatment was 
not based on results from randomized trials. Studies have indicated that survival of patients 
with advanced EOC given postoperative chemotherapy is better than for patients not given 
chemotherapy96-103. The results from prospective, randomized trials on advanced EOC 
have shown that combination treatment with carboplatin and paclitaxel is more effective 
than other regimens104-106. During the time period 1984 – 2001 a study from the Norwegian 
Radium Hospital demonstrated improved survival for EOC patients in the last five–years 
period. This improvement in survival was partly achieved by addition of paclitaxel107
(Figure 5). 
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Figure 5. Overall Kaplan–Meier survival curves by different chemotherapy regimens for 
epithelial ovarian cancers (EOC) patients FIGO IIIC, diagnosed in the period 1985 – 2000 
at the Norwegian Radium Hospital, P < 0.001107
The current standard treatment for advanced EOC in the western world is primary 
maximal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel every 
three weeks. The patients are followed with pelvic examination, CT scan (if measurable 
lesions), and CA–125 after 3 and 6 cycles. It is still debated whether the interval between 
surgery and first chemotherapy cycle has a prognostic role. In animal models short time 
interval between surgery and chemotherapy (SCI) improve survival108;109. This has not 
been supported by retrospective clinical studies110;111. In paper 3, we addressed this 
question by a prospective, population–based study.
The primary route of spread throughout the peritoneal cavity opens the possibility 
for therapy directed towards the peritoneal cavity. For many years clinicians have debated 
the role of intraperitoneal chemotherapy administration112-114. Armstrong et al. 
demonstrated that patients who received part of their chemotherapy by the intraperitoneal 
route had a median survival of 16 months longer compared to women who received 
intravenous chemotherapy only (65.6 versus 49.7 months)112. Present data indicate that 
cisplatin given intraperitoneally has a higher concentration in tumour cells compared to 
carboplatin112. Many research centres claim that intraperitoneal chemotherapy should be 
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offered as an option for optimally debulked EOC patients within randomized clinical trials. 
Intraperitoneal chemotherapy may be combined with hyperthermia, which enhances tissue 
penetration and cytotoxic activity of many drugs115-118. The role of hyperthermia in 
treatment of EOC is still not established. The current evidence for colorectal carcinoma 
with peritoneal carcinomatosis suggests that cytoreductive surgery combined with 
perioperative intraperitoneal chemotherapy is associated with improved survival compared 
with systemic chemotherapy119. This may also be the case for EOC. However, the patients 
receiving intaperitoneal chemotherapy had more serve toxicity (grade 3 – 4, fatigue, 
hematologic, gastrointestinal, metabolic, and neurologic). Only 42 % of the patients in the 
intraperitoneal group completed six cycles compared to 83 % in the intravenous group112.
Few patients completed the intraperitoneally treatment, thus there was a selection of 
patients to this treatment. The intravenous route is still the recommended administration 
route of chemotherapy for patients outside clinical trials. 
In a large prospective, randomized European study120 the role of neoadjuvant 
chemotherapy in advanced EOC in reducing tumour volume before surgery has been 
addressed. The study was closed in 2006 after recruitment of the estimated number of 
patients. Retrospective studies, however, have shown benefit for neoadjuvant 
chemotherapy121;122, while a prospective study from the United States did not123.
New therapies 
In frontline therapy trials, two design strategies are employed. 1) The novel agent 
may be administrated concurrently with standard chemotherapy showing promising results 
for some drugs124. 2) Alternatively, the agent may be given following the standard 
treatment as maintenance therapy125.
Clinical trials so far have shown little effect of chemotherapy in combination with 
small molecule inhibitors of metalloproteinases126;127. One of the most promising 
supplementary agents is the angiogenetic inhibitor, Bevacizumab. Several clinical studies 
in first–line treatment for recurrent EOC 128-130 and in other cancers 131;132 have been 
carried out using Bevacizumab. Two prospective, randomized trials (GOG study 218 and 
ICON7) are ongoing, treating the patients upfront with standard chemotherapy carboplatin 
(C) and paclitaxel (T) and in the experimental arm addition of Bevacizumab (B) or placebo 
(P). The addition of Bevacizumab is also given as maintenance therapy in one study arm 
and placebo in the two other arms (C + T + P o P; C + T + B o P; C + T + B o B). 
There is some evidence to suggest that adjuvant radiotherapy after radical surgery 
leads to increased disease–free survival for patients with advanced EOC. Intra abdominal 
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fibrosis after total abdominal radiotherapy does not seem to be a considerable problem133,
though many patients develop acute toxicity including diarrhea and abdominal pain. A 
considerable portion of patients develop chronic toxicity as fistulas, malabsorption, 
diarrhea, bowel adhesions and bladder problems 134. It is known from other studies that 
second malignancies might develop in the irradiated area after many years135;136.
Response evaluation 
In 2000 the response evaluation criteria in solid tumours (RECIST) was published137. At 
the moment CT scan is the most reproducible methods for measuring target lesions 
selected for response assessment in ovarian cancer. Patients participating in randomized 
trials should have defined target lesions up to a maximum of five lesions per organ and 10 
lesions in total. Target lesions should be selected on the basis of their size (those with the 
longest diameter). For practical reasons, only the largest target lesion is selected for 
patients outside randomized trials. 
The evaluation of response according of the WHO criteria: complete response—the 
disappearance of all target lesions and no new lesions; partial response—at least a 30 % 
decrease in the sum of the longest diameter of target lesions; progressive disease—at least 
a 20 % increase in the sum of the longest diameter of target lesions; stable disease—neither 
sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for 
progressive disease. 
In patients without visible target lesions on CT scan and patients outside of 
randomized trials other response criteria might be used: pelvic examination, vaginal 
ultrasound, serum CA–125 and chest X–ray. 
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BACKGROUND
The development of ovarian cancer surgery from the first described removal of an 
ovarian tumour in 1809138 until today has been accompanied with large improvements in 
operating techniques74-76;139-141, and health care organization 90;93;142. Introduction of 
chemotherapy143 was another major advantage in EOC treatment that has lead to improved 
survival96;100;102;103;107 (Figure 5). Despite these improvements, long–term survival for EOC 
patients is still inferior to many other cancer patients9. EOC has often been described as the 
“silent killer”8. Therefore, it was meaningful to describe the symptoms leading the patient 
to the health care system (paper 1). 
Randomization is the “gold standard” in clinical study design. However, patient 
selection is one of the limitations in randomized trials, which may make the studied 
patients non–representative for the whole patient population and the results less valid. The 
majority of EOC patients are not enrolled in randomized clinical trials. In the United 
States, only 6 % of these patients were enrolled in treatment trials144. During 2003, 49 out 
of 268 (18 %) stage II – IV EOC patients were enrolled in primary chemotherapy trials in 
Norway145. This demonstrates the need for a population–based prospective approach in 
order to overcome possibly biased results (papers 1 – 3). Knowledge of the patient’s 
disease based on the whole population with the specific disease within a geographic region 
is called “population adjusted clinical epidemiology”146.
Classical epidemiology deals with risk factors for development of disease, while 
clinical epidemiology describes individuals’ already experiencing disease. Rothman 
defined clinical epidemiology as: “….the study of illness outcomes in persons seen by 
providers of health care”147. In the present thesis the intention was to use a clinical 
epidemiological approach to demonstrate differences in outcome for different groups of 
EOC patients. The underlying research–question was whether patients received optimal 
treatment within the existing Norwegian health care system (papers 1 – 3). 
The relation between treatment levels and patient outcome is important in a public 
health perspective. The health care providers and policy makers might organize the health 
care in a more appropriate manner on basis of clinical epidemiological knowledge. 
In the United Kingdom the politicians wish welcome the development of multi–
disciplinary care, which might better the outcome for a variety of patient groups 148. This 
perspective also includes increased knowledge of tumour biology, which might improve 
the treatment (paper 4).
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MATERIALS AND METHODS
Study population 
The present thesis comprised 907 patients. Paper 1 enrolled all patients with EOC 
and BOT (n = 623) while paper 2 included stage IIIC EOC patients (n = 198) diagnosed in 
2002. Paper 3 comprised stage IIC to IV EOC patients (n = 371) with primary diagnosis 
2002 (n = 186) and 2003 (n = 185) receiving chemotherapy after surgery. Many patients (n 
= 384) were enrolled in more than one of the papers 1 to 3 (Table 4). In paper 4, S–BOT 
patients with and without non–invasive implants were selected randomly from the Cancer 
Registry diagnosed between 1985 and 1995 (n = 99). Paper 1 and 4 addressed different 
aspects of diagnostic procedures, while paper 2 and 3 concerned treatment outcome (Table 
3).
Organization and data collection 
OVANOR registry (Table 2) 
An important tool in the present thesis was the development of a prospective, 
population–based, clinical registration system for EOC, non–EOC and BOT in Norway. 
All epidemiological data were collected in accordance with the Cancer Registry 
regulations: § 1 – 7149.
A reference group of physicians from TH and NTH was established in 2000. The 
Cancer Registry invited physicians from all gynaecological units in Norway to participate 
in the reference group. It consisted of 18 physicians of whom one was a pathologist; one 
oncologist, one specialist in laboratory medicine, and the rest were gynaecologists. The 
reference group took part in the planning of a questionnaire, which was sent to all 41 
gynaecological units in Norway (Appendix 12.3). According to the answers, there were 
large variations in the treatment of patients with EOC in Norway 150. An extended clinical 
form for ovarian cancers was designed (Appendix 12.2). This clinical form replaced the 
standard Cancer Registry form. An electronic database was programmed in Firebird based 
on the data elements from the extended clinical form. 
The physicians responsible for medical examinations and treatment at the hospitals 
filled in the extended clinical form after January 1, 2002. The clinical form was returned to 
the Cancer Registry together with a copy of the surgical report within two months after the 
primary diagnosis. The pathological laboratories sent a mandatory copy of the pathological 
and/or cytological report to the Cancer Registry. In cases of missing data, the medical 
report was requested. Information on chemotherapy was collected from the patient 
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administrative system for all hospitals in Norway. In some cases additional information 
was supplied from laboratory results, image description, and referral letter. The cause of 
death registry was used to obtain cause of death and date of death. Last observation and 
emigration were aquired from the National Population Registry151. A reminder was sent to 
the hospital if the new clinical form or surgical report was missing. The above mentioned 
data elements comprised the OVANOR registry (Table 2). Ovarian cancer patients enrolled 
in the main Cancer Registry were compared with patients enrolled in the OVANOR 
registry in order to identify missing patients in the latter registry and vice a versa. All 
missing patients were then enrolled in the OVANOR registry. 
Table 2. Flow chart of information flow from different health care levels to the Cancer 
Registry of Norway, paper 1–4
Health care level
Gen. practitioner               Teaching hospitals (TH)               National registries 
Gen. gynaecologist               Non–teaching hospitals (NTH) 
Clinical form*                                                                                       Cause of Death 
Surgical report*                                                                Registry* 
Pathological report* 
Medical report* 
Patient                Referral letter**                                         Cancer Registry 
         of Norway 
Referral letter 2** 
Patient administrative system** 
Laboratory result**                                     National Population 
Image description**                                                                   Registry* 
*Basic sources, **Additional sources 
BOT registration 
The patients enrolled in paper 4 were identified in the main database of the Cancer 
Registry on basis of tumour localization, ovary (ICD10: C56)152 and serous papillary 
borderline tumour with and without corresponding non–invasive implants (SNOMED 
codes: 8440, 8441, 8442, 5850, 8451, 8452, 8462, 8560)153. The paraffin embedded tissues 
were collected from 19 pathological departments in Norway. The paraffin–embedded 
blocks were assigned a unique block–number (200 to 828) and an archive card was filled 
in for each paraffin block with the block number and patient ID–number (1 to 158). All the 
paraffin–embedded tissues were stained using the immunohistochemical method at the 
laboratory for pathology, the Norwegian Radium Hospital. Two pathologists (JMN, AB) 
independently scored the immunohistochemical stained slides. Information about medical 
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history, symptoms and treatment were collected from old clinical forms and pathological 
reports in the main Cancer Registry database. Surgical reports and medical records were 
requested from the hospitals where the primary treatments were performed. The current 
thesis is based upon data from OVANOR registry and the main database of the Cancer 
Registry.
Study design and follow–up (Table 3) 
Paper 1 is a population–based, cross–sectional register study of EOC and BOT. 
Paper 2 and 3 were prospective, population–based cohort studies of EOC, where the 
patients were followed to death, last observation or emigration. According to data from the 
Cause of Death Registry151, the cause of death was ovarian cancer (ICD–10, C56)152 for all 
patients, but one, who died of lung cancer in 2002. This patient was omitted from the 
analyses. The survival in paper 2 and 3 was measured as cancer specific survival. 
Paper 4 is considered a retrospective, population–based study of S–BOT comparing 
two groups (group with non–invasive implants and group without non–invasive implants) 
with regard to immunohistochemical staining (MMP–2, MMP–14, TIMP–2, VEGF, 
VEGFR–1, and VEGFR–2) of the the primary ovary tumours and the non–invasive 
implants. The cohort was followed to recurrence or January 1, 2006. Data of recurrence 
were obtained from surgical reports and pathological reports archived at the Cancer 
Registry. The survival was measured as disease–free survival. 
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Table 3. Overview of design and analytic models, paper 1–4 
Characteristics Paper 1 
Symptoms and referral 
Paper 2 
Surgery and 
operating hospital
Paper 3 
Surgery–chemo. 
interval 
Paper 4 
MMP expression in S–
BOT
Design Population–based, 
cross sectional register 
study with follow–up to 
first treatment 
Prospective, 
population–based 
register study with 
follow–up to death 
or last observation 
Prospective, 
population–
based register 
study with 
follow–up to 
death or last 
observation 
Retrospective pop.–
based register and 
laboratory 
study with follow–up to 
recurrence or last 
observation 
Analytic method Multinominal logistic 
regression 
Nonparametric tests of 
the median 
Binominal logistic 
regression 
Cox proportional 
hazard model 
Kaplan Meier 
Log rank test 
Cox proportional 
hazard model 
Kaplan Meier 
Log rank test 
Mann–Whitney: 
non parametric 
independent sample test 
Wilcoxon: 
non parametric 
two related sample test 
Kaplan Meier 
Log rank test 
Start of follow–up Date of 1. symptom 
Date of 1. dr.consult. 
Date of admission 
Date of primary 
surgery 
Date of 
1.chemotherapy 
cycle
Date of primary surgery 
End of follow–up Date of 1. operation 
Date of 1. chemo.cycle 
or December 31, 2002 
Date of death or 
March 31, 2004 
Date of death or 
May 31, 2005 
Date of recurrence or 
January 1, 2006 
Measure of effect Hazard ratio (HR) 
Odds ratio (OR) 
Hazard ratio 
(HR)
Survival Cancer specific 
death
Cancer specific 
death
Disease–free survival 
Variables (Table 4) 
Prognostic variables (factors) identified at time of primary diagnosis were as follows: 
residual disease, histologic type (serous or nonserous), grade of differentiation154, degree of 
atypia, presence of ascites, age, physical performance status33, serious comorbidity 
(defined in paper 3), postoperative chemotherapy, serum CA–125, and DNA ploidy. 
Explanatory variables 
Clinical variables 
The explanatory variables were different among the papers depending on the aim. 
The symptoms were grouped into 10 categories based on information in text files from the 
previously described sources (Table 2). Hospital units were defined as the first unit the 
patient was referred to (GYN, surgical, medical and other units). The hospital level was 
divided into the two categories TH and NTH (page 14). The specialty of the operating 
physicians was based on the specialty approval from the Ministry of Health in Norway. 
Being a specialist in gynaecological oncology was defined as having worked at least one 
year at the Norwegian Radium Hospital, because no formal specialty in gynaecological 
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oncology exists in Norway. The interval between surgery and first chemotherapy cycle 
(SCI) was defined as date from primary surgery to date of first chemotherapy cycle. 
Table 4. Overview of patient population and main variables and design, paper 1–4 
Characteristics Histology Paper 1
Symptoms and 
referral
Paper 2 
Surgery and 
operating 
hospital
Paper 3 
Surgery 
chemotherapy 
interval 
Paper 4 
MMPs
expression in 
S–BOT 
Year of prim. diagnosis 2002 2002 2002–03 1985–95 
Number of patients BOT 
EOC
137 
486 
–
198 
–
371 
99
–
FIGO stage IA–IV IIIC IIC–IV IA–IIIC 
Prognostic variables 
Residual disease x x
Hist./ hist.grade/atypia x x x
Ascites x x x
Age x x x x
Performance status x x x x
Comorbidty x xa
Chemotherapy x x x
CA–125 x x x
DNA ploidy x
Explanatory variables Symptoms 
Hospital units 
Hospital level 
Specialty
SCI MMP–2+14 
TIMP–2
VEGF 
VEGFR–1+2 
a Analysed, not published 
Immunhistochemical variables (Table 5) 
In paper 4 we examined MMP–2 and MMP–14 antibodies and their inhibitors 
(TIMP–2) together with VEGF and VEGFR. Five monoclonal antibodies (MMP–2, MMP–
14, TIMP–2, VEGF, and VEGFR–2), and one polyclonal antibody (VEGFR–1) were used 
for staining. Appropriate negative and positive (placenta) controls were used in each 
staining run (Table 5). 
Table 5. Characteristics of immunhistochemical antibodies, paper 4 
Antibody Clone Animal Company 
MMP–2 Mono Mouse Lab Vision 
MMP–14 Mono Rabbit Lab Vision 
TIMP–2 Mono Rabbit Lab Vision 
VEGF Mono Mouse Santa Cruz 
VEGFR–1 Poly Rabbit Santa Cruz 
VEGFR–2 Mono Mouse Chemicon 
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Quality of data “Cross–checking procedures” 
In cases where basic data were missing, a reminder was sent to the hospital. The 
data elements used in paper 2 were returned to the hospitals where primary surgery was 
performed (TH: Universitetssykehuset i Nord Norge, St. Olav Hospital, Haukeland 
universitetssjukehus, Rikshospitalet–Radiumhospitalet; NTH: Sykehuset Østfold, 
Stavanger universitetssjukehus). The majority (n = 124, 63 %) of the patients were 
operated at these hospitals and they had the first chemotherapy course at TH. The 
physicians responsible for the treatment checked the accuracy of data and returned the 
corrected data. Three of 313 dataelements (1 %) contained errors. One hospital was coded 
as NTH (correct: TH), CA125 was coded in the interval 36–150 (correct: > 150), and 
performance status according to WHO as 0 (correct: 1). The data errors were corrected in 
the OVANOR registry. After correction, less than 1 % of the dataelements used in the 
analyses may contain errors, if we presumed that the data not cross–checked also contained 
1 % errors. All immunhistochemical data were coded directly into SPSS. The data 
completeness was high (61–100 % in paper 1, 82–100 % in paper 2, 92–100 % in paper 3). 
In the retrospective S–BOT study, the completeness was lower (35–100 %, Appendix 
12.4).
If the information from the clinical form was inconsistent with information from 
other sources (surgical, pathological reports and medical records) the data was changed 
according to the presumed correct value. Example: the clinician staged the tumour to IIIC 
and the cytologist discovered malignant cells in the pleural effusion, the stage was then 
corrected to IV in the OVANOR registry (Appendix 12.1)61.
Statistical analyses (Table 3) 
All analyses were performed with SPSS for Windows (versions 11.5 – 12.01, 
Chicago, IL). Chi–square tests were used in the cross tables. To test correlation between 
prognostic variables, Spearman correlation factor was calculated. The survival pattern 
between various groups was displayed as Kaplan–Meier plots. The log–rank test was used 
to calculate differences in survival between the various groups. The Cox proportional 
hazard model was used to estimate the effect (as hazard ratios, HR) of the prognostic 
variables on survival. A binominal logistic regression model was used to examine the odds 
ratio (OR) associated with optimal chemotherapy. 
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In paper 4 the Kappa coeffecient was used to test the agreement between two 
independent pathologists’ scoring of immunhistochemical stained slides. 
Three comparisons were made, (I) nonimplant ovaries with implant ovaries, (II) 
nonimplant ovaries with implants, and (III) implant ovaries with corresponding implants 
(Figure 7). In analyses I and II, the Mann–Whitney test was used to test the differences in 
immunhistochemical staining between the implant and nonimplant groups. In analysis III 
the Wilcoxon signed rank test was used to test the difference between primary tumours and 
their associated implants. 
Non-
implant
ovary
Implant
ovay
IIIII
Implant
I
Figure 7. Scheme of tumour spread 
SUMMARY OF EACH PAPER
Paper 1 
All women diagnosed with epithelial, ovarian, tubal, and peritoneal cancer (EOC, n 
= 486), and borderline ovarian tumours (BOT, n = 137) in Norway during 2002 were 
enrolled in this study. 
Sixty–one percent of women with EOC were referred to GYN units, while 24 % 
were referred to surgical and 14 % to medical units. ‘Abnormal menstrual or vaginal 
bleeding or discharge’, were more frequent symptoms among patients referred to GYN 
units. ‘Abdominal pain or discomfort’ was the most common symptom among women 
referred to GYN and surgical units while women suffering from one or more of the 
symptoms ‘bowel irregularity’, ‘pain outside the abdominal cavity’, ‘persisting fatigue or 
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weight loss’, ‘respiratory difficulties’ and ‘other symptoms’ were most likely to be referred 
to a medical unit. 
A treatment delay was experienced by women referred to surgical and medical 
units compared to those referred to GYN units (mean, 20 and 24 versus 11 days). Forty–
five percent of women with EOC visited their general practitioner or private gynaecologist 
within three months from onset of first symptom. The physicians referred the patients to 
the hospital within one year from the first consultation in 94 % of the cases. 
Paper 2
All stage IIIC EOC patients (n = 198) that underwent primary surgery followed by 
chemotherapy (n = 175) or having three courses of neoadjuvant chemotherapy (n = 23) 
during 2002 were selected. 
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Figure 8. Kaplan–Meier survival curves for advanced ovarian/peritoneal/tubal cancer 
(EOC) by hospital level where surgery is performed. Log–rank test, P = 0.02. TH, 
Teaching hospitals, number of patients treated 108, (57 patients are dead at end of follow–
up). NTH, Non–teaching hospitals, number of patients treated 90 (58 patients are dead at 
end of follow–up) 
The short–term survival benefit at 450 days for patients operated at TH compared 
to NTH was 17 %. After 3 years of observation a survival benefit for patients operated at 
TH still exist (Figure 8). The risk of death within 600 days was 1.8 (HR) times higher at 
NTH compared to TH after simultaneously adjustment for seven prognostic factors. The 
women operated on by specialized compared to general gynaecologists had a 20 % 
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increased survival at 450 days (P < 0.0001). We confirmed that tumour reduction to no 
residual disease significantly improved survival. 
Paper 3
All EOC patients in stages IIC – IV (n = 371) during 2002 and 2003 were selected. 
These patients underwent primary surgery and were then treated at different time intervals 
by chemotherapy. 
No difference in survival between patient groups was seen when time between 
surgery and start of chemotherapy (SCI) was divided into quartiles. The group of patients 
with SCI less than six weeks had inferior survival if they had residual disease compared to 
those without residual disease after surgery, adjusted HR = 2.4. However, in the patient 
groups with SCI more than six weeks, there was no significant difference in survival 
between patients with and without residual disease. Unadjusted, HR = 1.6 adjusted HR = 
1.4).
Paper 4
The population comprised 99 patients with S–BOT with primary diagnosis between 
1985 and 1995, 44 with non–invasive implants and 55 without non–invasive implants. 
Strong positive MMP–2 staining was found more frequently in women with primary S–
BOT with non–invasive implants (76 %) compared to those without implants (53 %, p <
0.05). Expression of MMP–2, MMP–14, and TIMP–2 was similar in primary tumours and 
in their corresponding non–invasive implants. Most tumours had no VEGF expression (84 
% versus 82 %), while moderate to strong expression of VEGFR–1 and VEGFR–2 was 
detected in 79 – 94 % of tumours from both patient groups (nonsignificant). Three patients 
relapsed as invasive and four as borderline tumours.
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DISCUSSION
Methodological issues 
The data elements were precisely defined before starting the studies. The 
completeness and quality of data was continuously secured by reminders and cross–
checking procedures. Diagnostic procedures and treatment of S–BOT might have changed 
during the time period 1985 to 1995. In the period 2002 to 2003 diagnostic procedures, 
surgery and chemotherapy, did not change much, therefore the results were reliable for all 
patients studied. In study 2 and 3 the observation time was short, however, EOC patients 
treated with combination of paclitaxel have a median survival of aproximatly 32 months107
therefore short observation time is sufficient to record differences in survival among the 
study group of advanced EOC patients. 
Precision is defined as lack of random error. Two ways of improving precision are 
described: the first by increasing the size of the study and the second by increasing the 
efficiency with which information is obtained from the patients147.
            The number of patients studied in the present thesis was relatively small, but large 
enough to give answers to the aims of the thesis. In epidemiological, prospective 
population–based studies there is no need for large studies, if the differences in outcome 
between the patient groups are substantial and the quality of the data is good. 
           The information obtained from each patient is precise because of numerous data 
sources and cross–checking procedures. The proportion of missing data was decreased 
from paper 1 to 3 because the data collection had been carried out for another year, 
supplying more data. The sample size in paper 4 was larger than the estimated number of 
28 patients needed in each group calculated before study start. 
           The proportion of missing data was higher in paper 4 due to the retrospective design 
and long follow–up. 
Selection bias is present when the study population is not representative for the population 
in focus147.
       The Cancer Registry contains information on all patients with invasive cancer in 
Norway, resulting in little selection bias155-157. However, there might be a selection bias in 
referral to the various hospitals. During 2002 and 2003 the hospitals in health region South 
and some of the hospitals in region East and West referred the patients to the Norwegian 
Radium Hospital. Except for the latter hospital, the other hospitals making up the TH 
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group had emergency services. The patients referred as an emergency were equally 
distributed between the groups TH and NTH (emergencies: 9 %), hence the emergency 
help did not present any selection bias. 
Information bias in evaluating an effect can occur from errors in obtaining the information 
and measurements of subjects147.
       A misclassification of epithelial ovarian cancers might occur since not all 
pathologists have specialized knowledge about gynaecological pathology. A Norwegian 
study showed that the completeness of ovarian cancer is close to 100 % in the Cancer 
Registry when a second pathologist reviewed the specimen157. The deficiency in reporting 
of prostate cancer was less than 1 %. The validity control revealed errors in only 0.5 % of 
the data elements155, which was in accordance with the findings of EOC in the present 
thesis. Metastasis from other primary sites might also have been coded as primary ovarian 
cancer, but this misclassification is a minor problem. 
The non–operated patients had a higher risk of being misclassified than those 
operated. In 13 out of 486 patients (< 3 %) no histological or cytological information were 
available (Table 6). This misclassification might play a role in paper 1, since patients that 
were not operated on were included in the analyses (53 out of 486). However, none of the 
not operated patients were included in paper 2 to 4. 
Table 6. The basis for the diagnosis in the Cancer Registry among patients with invasive 
epithelial ovarian/tubal and peritoneal cancer with primary diagnosis 2002, n = 486, 
paper 1 
Diagnostic characteristics 
Patients operated 
n = 433 ( %)a
Patients not operated 
n = 53 ( %)a
Histology 431 (99.5) 15 (28) 
Cytology, only 2 (0.5) 21 (40) 
Autopsy, only 0 4 (8) 
Missing/not analyzed 0 13 (25) 
Sonography, and/or 
CT and/or MRI 424 (98) 53 (100)b
Missing 9 (2) 0
CA–125 355 (82) 41 (77) 
Missing 78 (18) 12 (23) 
CEA 0 22 (42) 
Missing 433 (100) 31 (58) 
Clinical diagnosis only 0 1 (2) 
Clinical and other diagnostic 
information 433 (100) 52 (98) 
a 62 patients out of 486 were not treated with chemotherapy 
b Sonography, n = 38, CT and/or MRI, n = 36
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Confounding occurs when an estimate of the association between an exposure and an 
outcome is mixed up with the real effect of another exposure on the same outcome, the 
two exposures being correlated158.
        Confounding must be a relative strong risk factor before the outcome is  
changed 147. We did not identify any important confounders. 
External validity (generalizability) is accomplished if the conclusions in a specific study 
can be applied on a group of patients not enrolled in the study147.
         We used population–based studies to accomplish high external validity. The 
findings in the thesis will be valid for similar patient populations. Although, the findings 
might not have external validity to populations with other genetic dispositions or treated in 
different health care systems. 
Discussion of the results
Paper 1 
The frequency of specific symptoms in paper 1 was lower than in an investigation 
based on a survey sent to ovarian cancer patients8. The use of patient’s self–report might 
give higher frequency of symptoms than information based on medical records159. The 
incidence of having any symptom did not differ much between our findings (94 %) and a 
previous investigation by Goff (95 %)8. Vine et al. reported that 90 % of EOC patients had 
symptoms160. Information on symptoms based on medical records did probably give valid 
data compared to patient questionnaires. The median duration of symptoms was longer in 
the latter study than in ours, 4 compared to 2.4 months160. A standardarized in–person 
questionnaire was conducted in the latter investigation. There might be a recall bias from 
patients or lack of appropriate reporting from the physician in our work. However, the 
results did not differ much between other studies and ours, thus this bias is of minor 
importance. 
The majority of EOC patients had symptoms before referral which did not support 
the statement of ovarian cancer as “silent killer” 8. Further, most of the early stage EOC 
patients had symptoms as well, 87 % in our study compared to 90 % in a recently 
published study by Latifeh161. A textbook7 maintained that 75 % of women presenting with 
ovarian cancer had symptoms, while we found 94 % of women with EOC and 75 % with 
BOT had symptoms . BOT patients reported a lower frequence of symptoms and they saw 
their general practioner later after onset of symptoms compared to EOC patients, which 
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might be explained by the lesser tumour spread at primary diagnosis (Figure 2) and slow 
tumour growth. These findings was in accordance with a previous study160.
Many patients were initially referred to surgical and medical units, probably 
because the physician interpreted the symptoms (‘bowel irregularities’, ‘pain outside the 
abdomen’, ‘repiratory difficulties’) as representing a non–gynaecological disease. A 
treatment delay was observed for patients that were first referred to surgical and medical 
units, probably due to a delay in diagnosis. 
Vaginal bleeding or discharge was seen in 14 % of the women with EOC and 16 % 
of those with BOT. This was in contrast to a Sweedish textbook6, where vaginal bleeding 
was reported in only 5 % of the cases. Patient information obtained from physicians’ 
recordings were probably less accurate than information obtained from patient 
questionnaires162;163. In spite of this, the frequency of symptoms based on physician’ 
recordings were higher in the present thesis than in the textbooks. May be there is a need to 
rewrite these textbooks. 
Only patients with epithelial ovarian cancers were enrolled in paper 1, and we do 
not know how many patients seeing their primary physician with the same symptoms 
having other diseases. General practioners in East London referring women to screening 
because of symptoms suspect of EOC found that patients with abdominal pain and 
distention without non–abdominal symptoms were more likely to have EOC than patients 
with both abdominal and non–abdominal symptoms164.
Paper 2 
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Figure 9. Kaplan–Meier survival curves for advanced ovarian/peritoneal/tubal cancer 
(EOC) by specialty of operating physicians performing initial surgery. Log–rank test, P < 
0.001. Specialist gynaecologist, number of patients treated 75, (38 patients are dead at end 
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of follow–up). Gynaecologist, number of patients treated 99 (58 patients are dead at end of 
follow–up). Surgeons, number of patients treated 24, (19 patients are dead at end of 
follow–up) 
The present thesis comprised the first prospective study to demonstrate improved 
survival of EOC patients treated at TH compared to NTH and improved survival when 
treated by specialist oncology gynaecologists compared to general gynaecologists (Figure 
9). The hospital level and surgical skills influenced the survival outcome for EOC patients. 
Other authors came to the same conclusions based on retrospective study designs72;90. The 
present study had a shorter observation time compared to Junor and Engelen. After a 
follow–up of three years there is still a significant difference in survival between TH and 
NTH (Figure 8 and 9). 
Other investigators have shown that more extensive surgery is carried out at TH. 
The operating physicians at TH performed lymphadectomy more often than physicians at 
NTH165. In paper 2 we defined stage IIIC on basis of positive lymph nodes as lymph nodes 
equal or larger than 2 cm61. In our paper, ten patients were staged IIIC on basis of positive 
lymph nodes (t 2 cm), eight of these patients were operated at TH and two at NTH. When 
these patients were omitted from the analyses, the survival did not change significantly. 
The more frequent upstaging of EOC patients at TH could not explain the difference in 
survival between TH and NTH. However, a recent study demonstrated the necessity for 
stratifying patients classified as having stage IIIC disease based on nodal disease only 
when comparing outcomes166.
In the present study the postoperative mortality was 5.6 %. This was in accordance 
with investigations on colorectal cancer167;168. In an investigation on EOC the 
postoperative mortality was only 1 %169. This low mortality might be due to patient 
selection. A higher postoperative mortality (death within 30 days after operation) at one 
treatment level might invalidate the analyses. There were more patients dying short time 
after surgery in the NTH group in our study (NTH, n = 10 versus TH, n = 1). Allthough, if 
these patients were excluded from the analyses, the hazard ratio did not change 
significantly.
In the present paper a comorbidity score with two levels were used for adjustments. 
This score was not evaluated against mortality. We therefore calculated a comorbidity 
score later, based on a scale (0 – 4) that was evaluated against the mortality in a breast 
cancer population (Charlson score)170. The patients in paper 2 had increased mortality with 
increased Charlson score (except for score 2). This score was distributed equally between 
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the hospital levels (TH versus NTH). The Charlson score did not change the hazard ratios 
after adjusting for all prognostic factors. 
The most important prognostic factor was when the operating physician achieved 
no recidual disease, which was in accordance with other investigators68-73;171. Aletti 
demonstraded that overall, residual disease was the only independent predictor of 
survival171. Further we demonstrated differences in survival among the TH (Figure 10). All 
TH have a potential to improvement. The number of patients’ optimally debulked (0 cm 
residual disease) might be increased at all TH (Table 7). One way to aceive this goal is to 
incorporate extensive upper abdominal procedures into the operative strategy. This may 
increase the rate of primary optimal cytoreduction without increasing perioperative 
morbidity and mortality172
Table 7. The residual disease achieved at the different TH among patients with invasive 
epithelial ovarian/tubal and peritoneal cancer (EOC) with primary diagnosis 2002, n = 
198, paper 2 (Pearson P = 0.015) 
Residual 
disease
TH1 TH2 TH3 TH4 NTH
0 cm 18 (40) 8 (35) 4 (14) 2 (18) 15 (17) 
> 0 cm 27 (60) 15 (65) 25 (86) 9 (82) 75 (83) 
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Figure 10. Kaplan–Meier survival curves for advanced ovarian/peritoneal/tubal cancer 
(EOC) by TH and NTH. Log–rank test, P = 0.02. TH1, number of patients treated 45, (19 
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patients are dead at end of follow–up). TH2, number of patients treated 23 (12 patients are 
dead at end of follow–up). TH3, number of patients treated 29, (18 patients are dead at 
end of follow–up), TH4, number of patients treated 11, (8 patients are dead at end of 
follow–up), and NTH, number of patients treated 90, (58 patients are dead at end of 
follow–up) 
Paper 3 
In a murine model the greatest effect on residual tumour growth and survival 
occurred when chemotherapy was given at day of surgery and not as effective if given 7 
days after surgery109. In retrospective human studies the length of SCI did not influence 
survival110;111. The present prospective and population–based study confirmed the findings 
in the previous human studies. However, no human studies have compared chemotherapy 
given at day of surgery compared to chemotherapy given several days after surgery as done 
in the murine model109.
The six weeks SCI was used because patients waiting more than six weeks often 
are excluded from chemotherapy phase III trials. When dividing the SCI into more equally 
distributed groups (< 4 weeks, n = 198 and t 4 weeks, n = 178), no major changes were 
seen in the Cox estimates. The majority of patients having chemotherapy within four 
weeks received their first cycle before leaving the hospital after surgery. A previous study 
used quantiles of intervals111, while another study used intervals shorter or longer than the 
median110.
In the survival analyses we chose follow–up from date of first chemotherapy cycle 
and not date of primary surgery, because the patients treated with chemotherapy more than 
six weeks after surgery would otherwise have a guaranteed survival of six weeks and could 
give bias to the analyses. 
New analyses were made to illuminate the question why patients (76 out of 371 had 
SCI > 6 weeks) had delayed SCI. Hospital level and co–morbidity (defined in paper 2, no 
co–morbidity, n = 335, co–morbidity, n = 39) were introduced in the analyses. When these 
two variables additionally were corrected for in the Cox analyses, only small changes were 
seen in the estimates. The conclusions in the paper were not altered by these new analyses 
(Table 7). These results were not published in the paper.
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Table 8. Hazard ratios (HR, 95 % confidence intervals, CIs) for patients with advanced 
ovarian, tubal or peritoneal cancer (EOC) who received chemotherapy at different 
intervals after primary surgery (SCI); Cox regression, paper 3 
Residual
disease
status
Interval 
(weeks) 
SCI
No. of 
patients Unadj. CI
Adjusted for 
7 prognostic 
Variables
HR
CI
Adjusted for 
9 prognostic 
Variables
HR
CI
None < 6 82 1 1 1
t 6 24 1.86 0.75 – 4.61 1.35 0.51 – 3.56 1.53 0.57 – 4.05 
Residual
disease
< 6 213 3.66 2.09 – 6.40 2.36 1.22 – 4.57 2.55 1.31 – 4.96 
t 6 52 2.67 1.35 – 5.28 1.64 0.76 – 3.57 1.69 0.77 – 3.71 
Patients operated at TH received their first chemotherapy cycle earlier than patients 
operated at NTH (24 versus 36 days, Table 9). This was probably due to the time delay 
when referring the patients from NTH to TH after surgery. The first chemotherapy cycle is 
mostly given at TH. 
Table 9. Time from surgery to first chemotherapy cycle, paper 3 
Time from surgery to first 
chemotherapy cycle 
TH (n = 194) 
Time from surgery to first 
chemotherapy cycle 
NTH (n = 177) 
Mean (days)1 24.0 36.3 
Median (days) 20 35
Range (days) 5 – 87 1 – 118 
1Independent sample t–test, P < 0.001 
A recent study showed that patients debulked to less than 2 cm had a longer 
progression free survival if the patients had less extensive disease at the onset of 
chemotherapy79. Makar found that patients in stages IIIA–B with no residual disease have 
improved overall survival compared to patients in stage IIIC with no residual disease after 
primary surgery173. The present thesis gave weak support to this finding. The survival was 
slightly improved in the group with less extensive disease before surgery. In the present 
thesis a non–significant increased risk of dying was seen in stage IIIC with no residual 
disease after primary surgery after correction for 7 prognostic factors in the Cox analyses. 
Unadjusted HR = 1.2 (CI 0.5–2.7) and adjusted HR = 2.3 (CI 0.7–7.6). 
It would be of interest to assess the impact of delayed chemotherapy on time to 
recurrence rather than time to death. The cancer specific death might be influenced by 
many other factors than disease–free survival, including choice of therapy for recurrent 
disease. Reassessment of the data using this endpoint might be meaningful to perform in 
later analyses, but data on recurrence was not available in the present paper (page 45). 
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Paper 4 
           Many S–BOT recurrences occur several years after primary diagnosis. In order to 
have a follow–up on all patients of at least ten years, patients diagnosed between 1985 and 
1995 were selected. Long follow–up secured the majority of recurrences to be identified. A 
follow–up of at least 10–years is recommended by other authors174.
One limitation in study design was that lack of staining might indicate that antigens 
had vanished from the paraffin–embedded tissues during the years of storage. Some 
authors have observed that antigens had weaker staining after storage175;176. One 
investigation showed that using the tissue microarray technique for storage, the 
antigenicity decreased176. However, our tissue material was stored in paraffin–embedded 
blocks and we used different antigens. A difference in staining might have influenced the 
results in the analyses I and II, but not in III (Figure 7). 
In a previous study it was demonstrated that MMP–2 expression in S–BOT was 
more similar to expression in benign cysts than in EOC177. There was no significant 
correlation between VEGF and MMP–2 expression for S–BOT in the 
immunhistochemistry study of Garzetti et al., while the correlation was significant between 
VEGF and MMP–2 among the EOC patients178. Paper 4 is to our knowledge the first one 
to describe an association between MMP–2 and non–invasive implant formation in S–
BOT. The validity of this result must be confirmed by other studies. It is proposed that S–
BOT with micropapillary serous carcinoma or invasive implants might develop to well 
differentiated carcinomas19. However, we found that MMP were involved in non–invasive 
implant formation, which indicated that primary tumours with non–invasive implants 
might be a step along the “low–grade” pathway towards well differentiated carcinomas. 
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IMPLICATIONS
High–risk patients 
The ovarian consensus statement recommends prophylactic oophorectomy in 
women with hereditary syndromes (breast–ovarian cancer and Lynch syndrom), though it 
has not been scientifically proven that this approach increases survival among these 
patients179;180.
Screening
Currently, there are few international recommendations to introduce national 
screening programs in order to detect ovarian cancer at early stages. So far there is no 
evidence that screening in the general population would improve survival in EOC patients. 
Results from several large ongoing randomized trials will probably in the near future 
establish the impact of ovarian cancer screening on survival181.
 In these trials, the basic screening tools were still pelvic examination, CA–125 and 
vaginal ultrasound. The use of vaginal ultrasound might detect ovarian cysts with various 
grades of complexity. The more complex cysts, the more likely they were malignant. This 
method had low sensitivity and specificity181. In the last decades many new tumour 
markers and imaging techniques were tried out in order to detect ovarian cancer at earlier 
stages182. However, many countries have screening programs among high risk 
women183;184. The efficacy of such programs seems poor because the majority of cancers 
are still detected in advanced stages180. New technologies now exist that are required for 
the application of serum proteomics to cancer screening. Thus, there is a basis for 
optimism that novel approaches to cancer detection and screening will emerge soon182.
Symptoms
The general practitioner and gynaecologist must consider EOC diagnosis when 
women present with diffuse symptoms in the lower abdomen thus making earlier diagnosis 
possible. The general practioner and gynaecologist should ask about symptoms that are 
related to EOC on routine consultation185-187. If EOC is suspected, CA–125, vaginal 
ultrasound, pelvic examination, and CT scan should be performed. The primary physician 
might contribute to earlier diagnosis and treatment. 
Risk of malignancy index (RMI) 
In the clinical practice there is a need for techniques to discriminate benign from 
malignant ovarian tumours. The malignant tumours should be referred to specialized 
oncology centers (TH) for treatment, while women with benign tumours can be treated at 
local hospitals (NTH). Jacobs et al. developed the RMI based on clinical findings, 
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ultrasonography, serum CA–125, and menopausal status (Appendix 12.1)188. Several 
studies have confirmed the efficiency in using the index 93;189;190, but still this model only 
has a sensitivity of 78 % and specificity of 80 %191. In an attempt to increase the 
sensitivity, a prospective international multicentre study was carried out to develop a better 
model to distinguish between benign and malignant adnexal mass diagnosed before 
surgery191. Twelve variables were included in a logistic regression model: individual 
history of ovarian cancer, current hormonal therapy, patient age, maximum tumour 
diameter, the presence of pain during the examination, the presence of ascites, the presence 
of blood flow within a solid papillary projection, the presence of a purely solid tumour, 
maximal diameter of the solid component, irregular internal cyst walls, the presence of 
acoustic shadows, and the colour score. This model accomplished a sensitivity of 93 % and 
specificity of 76 %, and it is now prospectively evaluated. 
Centralization 
The present thesis has strongly contributed to the policy makers’ decision to 
centralize ovarian cancer surgery in Norway. Paper 2 has together with other studies given 
evidence to the benefit of specialization in gynaecological oncology10;72;90;192. The findings 
in the present papers also contributed to debate in the national press193.
The surgeons’ skills were shown to be an important factor to improve EOC 
patients’ survival. Patients operated by physicians that had operated more than ten 
advanced EOC patients per year had better survival (Figure 11).
Figure 11. Kaplan–Meier survival curves for advanced ovarian/peritoneal/tubal cancer 
(EOC) by number of operations per operating physicians performing initial surgery. Log–
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rank test, P = 0.1. Group with > 10 operations, number of patients treated 61, (32 patients 
are dead at end of follow–up). Group with 1–10 operations, number of patients treated 134 
(80 patients are dead at end of follow–up) 
One of the most important factors leading to improved survival was the physicians’ ability 
to optimally debulk the patients. The goal of the operating physicians must be to 
systematically remove all visible tumours in the abdominal cavity (Figure 12). 
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Figure 12. Kaplan–Meier plots. Three years survival of epithelial ovarian/peritoneal/tubal 
cancer (EOC) stage IIIC with primary diagnosis 2002 according to residual tumour more 
or equal to 0 cm in Norway, n = 198. Date of last observation January 1 2006. Log Rank 
Test, P = 0.0003. Data from OVANOR registry 
One manner to achieve this goal is to make a systematic description of pre– and 
post–operativ tumour volume and localization in the surgical reports. The suggested 
scheme (Appendix 12.5) might contribute to make this goal possible. It is important to 
describe the number and size of remaining tumour lesions in order to quantify the amount 
of total residual disease. In colorectal cancer a peritoneal cancer index is used to estimate 
the likelihood of complete cytoreduction in patients with peritoneal surface malignancy194.
Physicians operating EOC should remove the omentum in all cases. Also in BOT correct 
staging is important and implants should be biopsed. The operating physicians must 
remove suspected lesions from the abdominal cavity including implants, making a correct 
diagnosis possible. Still it is not known whether removal of these implants will contribute 
to improved survival48.
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Following publication of the data in the present thesis regarding advanced EOC 
treatment in Norway, the practice has changed. In 2005 a national concensus for 
centralization on ovarian cancer surgery in Norway was agreed on, however, not all NTH 
refer the patients to TH at the present time. 
Chemotherapy
Patients with low performance status might wait several weeks before 
chemotherapy after surgery without having inferior survival. These patients need to 
recover after surgery in order to tolerate chemotherapy. 
Surveillance and multi–disciplinary care 
The present thesis demonstrates how clinical prospective population–based studies 
contribute to knowledge on symptoms and treatment of EOC. Clinical registries are 
valuable tools for surveillance of many diseases. These registries contribute to valuable 
knowledge in guiding clinicians and health care administrators to manage the health care in 
an appropriate way for a variety of patients. 
The development of a multi–disciplinary approach might better the outcome for 
different patient groups148. This thesis demonstrates the importance of introducing the 
public health and epidemiological perspective into “small” specialties as gynaecological 
oncology195. It is reasonable to believe that large patient groups treated for similar diseases 
also have inferior outcome when treated in institutions lacking appropriate professional 
skill. The knowledge from this thesis might also be beneficial for these patient groups. 
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MAIN CONCLUSIONS 
The present thesis gave evidence to the positive effect centralization of surgery will 
have on survival for EOC patients. 
Paper 1 
More than one–third of EOC patients were referred to non–GYN units leading to 
delayed treatment. The majority of the patients had symptoms. The most common 
symptoms were ‘abdominal pain’ and ‘distended abdomen’. ‘Bowel irregularities’ without 
‘rectal bleeding’, especially in postmenopausal women were also common symptoms. 
Higher awareness of EOC symptoms might lead to earlier diagnosis and treatment, and 
possibly improve survival for these patients. 
Paper 2 
If the EOC patients were operated at TH or by specialists in gynaecological 
oncology, the short–term survival among these patients were improved. Centralization of 
surgery and formalized specialization in gynaecological oncology might improve survival 
for these patients. 
Paper 3 
Different SCI had no impact on short–term survival. Patients with low performance 
status may wait longer than six weeks before chemotherapy is given and these patients may 
be included in randomized phase III chemotherapy trials. 
Paper 4 
The interaction between S–BOT cells and peritoneum in formation of non–invasive 
implants may be influenced by the proteolytic activity of MMP–2. Patients with non–
invasive implants had a nonsignificant inferior disease–free survival compared to patients 
without non–invasive implants. 
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FUTURE PERSPECTIVES AND RESEARCH 
At the end of 2006, more than 3000 patients with ovarian cancer were enrolled in 
the OVANOR registry, which makes continued research on epithelial and non–epithelial 
ovarian cancers on a population level possible. Clinical information on each patient is 
registered in detail with high data quality. The present registry will enable researchers to 
give answers to many questions about treatment and outcome for these patients. Patient 
selection in randomized trials often makes biased outcome. Studies should be performed 
on this data collection with five–years survival follow–up. 
Surgical techniques have been introduced without randomized trials196. One 
approach in evaluating these new techniques is to perform population–based 
epidemiological studies in order to reveal possible differences in outcome between old and 
new treatment modalities (open surgery versus laparotomy or robotic surgery). The 
principle of population adjusted clinical epidemiology is now being implemented in 
Norway for other cancer types such as prostate and breast. The Cancer Registry is planning 
to build up clinical registries in collaboration with the clinicians for the other 
gynaecological malignancies. 
Epidemiological studies based on data from non–EOC are now possible to perform. 
During the five–years existence of the OVANOR registry, approximately 200 non–EOC 
are recorded. 
It is crucial for further development of the OVANOR registry that clinicians who 
are suppliers of data to the registry are working in close collaboration with those persons 
responsible for the registry. The reference group should make new guidelines for the 
OVANOR registry in collaboration with Cancer Registry. The reference group must 
approve protocols for doctoral thesis. The collaborating physicians and other health care 
providers should publish results from research in peer–reviewed journals. 
A build–up of bio banks linked to the OVANOR registry will strongly contribute to 
research on ovarian cancer. Molecular genetics and proteomics are two fields that have 
developed toward clinical applications. Based on a complete patient population one might 
target the genes most common in the development of ovarian cancer, especially if the 
population–based register is linked to bio banks. With biological material collected from 
the majority of the ovarian cancer patients, it will secure that the genes analyzed are 
representative for the whole patient population. 
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In clinical practice there is a need to develop prognostic tools to identify S–BOT 
patients with unfavorable prognosis (micropapillary serous carcinoma with invasive 
implants). These patients might benefit from more extensive surgical (oment and 
peritonectomy) and medical (cytotoxic regimens in combination with various noncytotoxic 
inhibitors) treatments given intravenously or intraperitoneally197. More 
immunhistochemistry studies of S–BOT with invasive implants and micropapillary 
architecture should be performed. 
The enhanced expression of MMP–2 in the non–invasive implant group indicated 
that treatment of selective MMP–2 inhibitors might be one way of preventing recurrence in 
these patients126;127;198-200. The invasive implant group might be the most suitable group for 
this therapy. Allthough, MMP inhibitors in phase III trials in invasive cancers have not 
demonstrated clearly improved overall survival, these inhibitors might prove to be 
effective of S–BOT with implants because the genetic alterations for S–BOT differ from 
that of high grade carcinomas (Figure 3)126;201.
The recent decision to discontinue reporting of BOT in the United States 
surveillance, epidemiology, and end results (SEER) program has eliminated a potentially 
valuable tool for identifying population–based cases in the United States 197. Therefore it is 
important that other national registries continue to enroll BOT patients. It is difficult to set 
the correct histologic diagnosis of BOT, therefore it is important to educate general 
pathologists with special knowledge of BOT pathology. One limitation for further studies 
in the clinic and laboratories is the relatively low incidence of S–BOT with invasive 
implants. Hence, an international collaboration work in the laboratories and clinicians 
should be established197.
New studies 
Influence of surgery chemotherapy interval (SCI) on disease–free survival 
New analyses will be performed of the patient cohort (n = 371) in paper 3. Time to 
recurrence will be used as end point (page 37).
Neoadjuvant chemotherapy 
Patients stage II – IV enrolled in the OVANOR registry with primary diagnosis 
2002 – 2005 receiving chemotherapy and surgery will be identified. The group receiving 
chemotherapy before surgery will be compared to the group having surgery initially. In this 
population–based prospective study we will also include patients not included in the 
international randomized EORTC study120.
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Capsule rupture during surgery 
A retrospective multi centre study from 2001 demonstrated inferior survival for 
EOC patients with stage I disease with capsule rupture during surgery202 . We are carrying 
out a Norwegian study including patients (n = 260) with primary diagnosis between 2002 
and 2004. Early stage EOC has good prognosis and recurrence might occur several years 
after primary treatment. Therefore, the observation time should be at least 3 to 5 years after 
diagnosis in order to record the majority of patients with recurrence. The outcome will be 
calculated as disease–free and cancer specific survival. 
Quality of life 
Relatively few studies have focused on quality of life measurements among EOC 
patients203-205. A study will be done, where a quality of life questionnaire is sent to 
randomly selected patients enrolled in the OVANOR registry. Patients treated for primary 
and recurrent disease will be included. Patients with recurrence are facing a non–curable 
disease, hence quality of life is an important outcome variable during and after treatment 
for recurrence. 
Ovulation induction and the risk of ovarian cancer 
By linking the OVANOR registry to the hospital registries performing in vitro 
fertilization in Norway, one might give answer to the question if ovulation induction 
increase the risk of ovarian cancer206;207. Women that have performed in vitro fertilization 
should be compared with a matched control group of women in the general population in 
order to calculate the standarized incidence ratio for developing ovarian cancer after in 
vitro fertilization. The OVANOR registry contains detailed information on all patients with 
ovarian cancer, why sub–analyses needed for such a study is possible to perform.
BOT studies 
In order to further illuminate the mechanisms of cancer development to highly 
differentiated EOC18;19, a study is planned using fresh specimen from cystadenomas, S–
BOT stage IA, S–BOT with non–invasive implants, S–BOT with invasive implants, highly 
differentiated EOC stage I and advanced stages. The specimen is collected prospectively 
from Rikshopitalet–Radiumhospitalet. We want to use micro array techniques for selected 
genes. The primary tumours, implants, and metastasis will be analyzed as a cross sectional 
study.
Later a follow–up study will be performed to identify prognostic factors useful for 
further studies. 
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